A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

NCT01328951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

643

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Placebo
DRUG: Erlotinib
DRUG: Second-Line Chemotherapy

Sponsor

Hoffmann-La Roche